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Introduction
Public goods, as well as commercial commodities, are 
affected by exclusive rights secured by intellectual prop-
erty (IP) rights. These rights serve as an incentive to invest 
human and material capital in research and development 
that is destined for a host of resources and goods. Particu-
larly in the life sciences, IP rights regulate objects such 
as food and medicines that are key to securing human 
rights, such as access to adequate food and the right to 
health (1, 25.1). Consequently, IP serves private and public 
interests. Private interests consist of being able to enjoy the 
fruits of one’s labor, and public interests entail the provi-
sion of current and future public goods. Extensive research 
and development (R&D) enterprises are made rentable as 
rights holders can market their products exclusively, se-
curing the existence of new commodities and due to the 
temporal limits of IP, also the provision of future goods, as 
resources become part of the public domain.
As costs of developing a merchantable product in the life 
sciences have risen (for a recent study in the area of phar-
maceutical see Munos, 2009 (1)), a more stringent market 
orientation has become more mandatory. Often, goods 
that were formerly free, must now be paid for by end-
users due to high product-development expenses. With 
worldwide income inequalities it is becoming evident 
that if economically under – or undeveloped groups and 
nations are not allowed to make use of the technologi-
cal innovations of developed countries, they may end up 
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even more impoverished and increasingly vulnerable both 
economically and geo-politically. Furthermore, objects 
predominantly needed in resource-scarce markets often 
are not developed, given that R&D expenses incurred 
(by either developed or underdeveloped nations) cannot 
be adequately recovered (this phenomenon is epitomized 
with the so-called “10/90 gap” (3,4)).
In order to discuss the implications of this status quo and 
the feasibility of alternatives, researchers and policymak-
ers were convened at a conference in Brussels at the end 
of September, 2011.
The grounding idea of the conference
How can appropriate IP regimes alleviate the huge welfare 
burden incurred by developing countries that engage pro-
gressive biotechnology? In other words, how can IP rights 
contribute to social justice? These questions prompted two 
Dutch research institutions – the Centre for Society and 
the Life Sciences and the Applied Philosophy Group (the 
position the group takes to this general problem is exempli-
fied in Korthals, Belt and Korthals and Timmermann and 
van den Belt (5-7)) at Wageningen University – to engage 
philosophers, sociologists, experts in IP law, patent exam-
iners, scholars and practitioners from biotechnology, al-
ternative business modelling, development aid, innovation 
studies, political science, as well as state representatives 
and EU officials, to discuss the ethical and social issues 
generated by current IP protocols and paradigms.
Scope of the problem
Research and development in the life sciences lead to huge 
business opportunities for knowledge economies, and also 
to possibilities for securing fundamental human rights, at 
national and international levels. The ever increasing glo-
balization of trade, epitomized by the worldwide imple-
mentation of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS), negotiated 1994, 
has been important to such global biotechnology com-
merce and the balance of IP (8). Without doubt, scientific 
innovation has greatly improved the overall quality of life 
in the developed world, as well as a longer life expec-
tancy, both due to a significant extent to achievements 
in biomedicine and in agrobiotechnology and nutrition. 
Indeed, science and technology could play a vital role in 
alleviating the predicament of developing and underde-
veloped nations of the world, in particular by reducing the 
18 million poverty related deaths. An extensive critique 
on negative influence of trade regimes on world poverty 
is offered by Pogge (9). But, given that much of science 
and technology is provided as proprietary commercial 
enterprise – and its allocation and sharing regulated by 
IP governance – we must ask if and how such IP statutes 
could and/or should be construed so as to better meet the 
social obligations of science.
Opportunities and reforms
No single solution will address the justice issues raised by 
the existence of intellectual property regimes – this was 
recognized and widely appreciated by the participants 
of the conference. A more scrutinous view of current IP 
schemes led to posing of three alternatives to existing IP 
regimes; these are 1) “open innovation”, 2) the “access to 
knowledge movement” and 3) the concept of a “health im-
pact fund”. The subjects were discussed in keynote lectures 
and dedicated workshops, and of particular note was an 
approach proposed for Brazil, a new emerging economy.
The current IPR regime
Nikolaus Thumm, Chief Economist of the European Pat-
ent Office, provided an overview of the justification of 
current IP regimes: The function of a patent is to address 
a particular market failure. Research and development 
costs, especially in biotechnology, are extremely high yet 
it is relatively affordable to reproduce a product once it has 
been developed. This reflects a lack of incentive to invest 
in research and development if/when there is little possi-
bility to recoup the expenses involved. This is where the 
patents come into play. An inventor has, under a given set 
of constraints, the option to apply for temporary exclusive 
rights if he is willing to disclose relevant information to 
assemble the object of innovation. In this way, civil soci-
ety limits what is presently in the public domain in order to 
secure the potential existence of future public goods. The 
nature of a patent is therefore instrumental: it is a tool to 
ensure that innovators who produce objects with reason-
able research and development costs, and that find a suffi-
cient market, will recover expenses and gain sufficient re-
sources to render such investment worthwhile and thereby 
continue to make those goods. However, there are limits 
to which inventions can qualify for exclusive rights. New 
market opportunities, or the enlargement of the knowledge 
pool, are not goals to be pursued at all costs; the percep-
tion that a patent might conflict the ordre public has roots 
anchored in patent law. (An early exposition of Thumm’s 
early perspective on the ethical implications of patenting 
is offered in Ibarreta and Thumm, 2002 (10)).
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The notion that patenting is good, more patenting is even 
better lacks empirical evidence. As too little protection 
of new inventions can limit the future existence of some 
goods, too much protection can also deter some innova-
tors from developing products in adjacent areas.
As well, patent offices offer civil society the possibility to 
file for appeals. This is an opportunity to instil checks and 
balances to confront possible negative effects upon public 
welfare that were not evident at the time of patent issue. 
The quality of patents in this sense therefore depends on 
the active engagement of civil society.
Open innovation
Richard Jefferson, Executive Director of Cambia, an 
autonomous not-for-profit organisation connected with 
Queensland University of Technology, Brisbane Australia, 
provided an overview of his efforts in making biotechnol-
ogy research and development more accessible. Concepts 
such as “open access”, “open source” and “open innova-
tion” address not only different levels of accessibility, but 
represent a sense of attitude and commitment to the pub-
lic (11). “Open innovation” does not mean free-of-cost, 
but free in the sense of being transparent and unrestricted. 
The complexity of IP regimes often poses a threat to the 
openness of science by adding uncertainty, and increasing 
risks of wrong or frankly socially disruptive investments. 
Jefferson’s soon to be released “The Lens”, is a public 
search tool that takes into account patent literature as well 
as incorporates more public databases and open access 
journal articles to both inform how R&D are done, who 
is doing R&D, and where R&D are being done (12). The 
question of whether openness leads to fairer distribution is 
something that remains unresolved until further research.
The workgroup discussions started with a short critical 
statement by Pieter Lemmens emphasising the role of com-
mons for the future production of knowledge and their po-
tential to rebalance uneven power relations. (P. Lemmens 
offers a wider introduction to his viewpoint (13)).
Access to knowledge
According to Carlos M. Correa of the University of Buenos 
Aires, there are two streams of the “access to knowledge” 
movement, one that aims to build an information society 
where knowledge is openly available without restriction, 
and a second that seeks a general expansion of the public 
domain. Correa posed the question of if and how can these 
ideas could be reconciled with initiatives for protecting 
traditional knowledge through exclusive rights? Many 
points of his talk can be found in Correa, 2010 (14). It be-
came clear that an attempt to protect traditional knowledge 
by exclusive rights was at odds with those philosophical 
approaches that are based on sharing, rather appropriating, 
knowledge. Still, a consistent issue in whether those con-
ventions are of actual interest to the individual indigenous 
communities, particularly the predominance of Western 
conceptions of intangible property with customary laws, 
and the extent to which various international statues might 
consider the nature of traditional knowledge. (This distinc-
tion is exemplified in Robinson, 2008 (15)).
Henk van den Belt re-introduced the topic in the espe-
cially assigned workshop with a short statement that 
started with an historical overview of the movement and 
ended emphasising the dual role of “access”: consump-
tion and participation.
The idea of an impact fund
Linking profits to exerting positive impact on urgent 
problems is of particular interest for the development 
of targeted products not covered sufficiently by market 
incentives (such as medicines for neglected diseases or 
improvements in agrosciences especially targeted for the 
needs of the poor). An elaborate proposal for this is the 
Health Impact Fund (16). Doris Schroeder, of the Univer-
sity of Central Lancashire (UK) and University of Mel-
bourne (Australia), noted that the idea behind the fund 
is to offer a reward to companies that aim at maximizing 
quality-adjusted life years (QALY) of people suffering a 
particular disease or disorder. While keeping IP rights, the 
company must be committed to sell medicines at cost-
price in order to be rewarded financially proportional to 
the product impact in increasing QALY.
Cristian Timmermann raised the problems involved in 
any proposal that leaves the current global distribution of 
IP rights intact. (A revised version of his statement can be 
found in Timmermann (in press) (17).
Of noted interest was how far the impact fund construct 
might be implemented in other areas, such as agriculture 
and climate change mitigation and adaptation. The main 
criticisms of the impact fund idea question the prerequi-
site of patents for fund rewards and the maintenance of 
current power relations. (Meanwhile Thomas Pogge has 
informed us that the revised version of the Health Impact 
Fund proposal has loosened up this criterion (16)).
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Emerging countries: Brazil as a case study. A delegate of 
the Brazilian Mission to the European Union, Eduardo 
Ferreira provided a detailed overview on the country’s 
new law on the protection of cultivars. Although the law 
was introduced in order to “1) facilitate the exchange of 
genetic material and the genetic enrichment of Brazilian 
agriculture 2) allow imports of commercial seeds and 3) 
assure that Brazil can export this kind of material”, it be-
came evident that the country was also aiming at a stron-
ger enforcement of exclusive rights granted to domestic 
and foreign seed producers and providing a safe harbour 
for foreign investment while improving the grounds for 
future scientific collaboration (18).
Problems
Different approaches underline the difficulties of generat-
ing revised or new IP regimes that more saliently reduce 
extreme poverty, powerlessness and vulnerability of indi-
viduals, communities and nations.
Human rights and IP rights
The right to adequate food and the right to health as per the 
Universal Declaration of Human Rights (1, 25.1) are not 
the only two rights that are potentially negatively affected 
by liberties granted by the use of exclusive rights secured 
by IP regimes (1, 25.1). There is a strong plea for a democ-
ratization of science, a demand for openness and inclusion, 
both in active participation and decision-making, that in 
the human rights discourse are encompassed in the right 
to share in the advancement of science (1, 27.1). There is 
a widespread indignation about the ways IP rights restrict 
freedom to operate, and constrict high-level science to be 
a luxury reserved for developed nations.
IP regimes could play a much more favorable role in 
improving global human welfare and in securing human 
rights (TRIPS, art. 6). At present, there is insufficient in-
centive to both provide innovations that would alleviate 
problems that predominantly affect the poor, and to make 
those innovations widely accessible.
European states have a long-standing tradition in secur-
ing their citizens the minimum requirements for adequate 
living standards. The successful eradication of extreme 
poverty in Western Europe has led to viewing poverty as 
a definitive harm to human welfare that is unacceptable, 
and also preventable.
Human rights commitments
Antony Taubman, Director of the Intellectual Property 
Division, World Trade Organization (WTO), addressed 
the role of exclusive rights when acknowledging intel-
lectual property, namely that society grants a temporary 
exclusive right for bringing into existence a future public 
good. Taubman noted that by revising theory and interna-
tional conventions there is no human right to intellectual 
property, rather only the right to benefit from the material 
interests of scientific production (1).
Some essential liberties are also affected by current IP 
regimes. We must ask ourselves if and to what level “indi-
vidualist atomistic innovation” will be favored at the cost 
of “cumulative, collective innovation of indigenous com-
munities”? Might this constitute a violation of rights, and if 
so, to which rights? Or, does this simply amount to a lam-
entable loss of diversity in scientific practices that could 
be deemed acceptable on utilitarian terms? This inevitably 
prompts the question of what human goods may be sacri-
ficed for efficiency in technological advancement?
IP rights and the needs of small and medium enterprises 
and industry
The current IP system has unintended consequences that 
render increasingly larger-scale players domination in the 
markets. This has a foreseeable adverse effect on the rate 
and quality of inventions, and the survival of small and 
medium size enterprises. In particular, newcomers from 
the developing world face numerous difficulties.
The Paris convention of 1883 largely set the “rules of 
the game” for patenting. The late 19th century was an 
era where differences between bigger and smaller com-
panies were less pronounced, and the implications of 
biotechnology were yet unforeseeable. We must ask how 
those rules might be out-dated, and what negative costs 
for public welfare and business opportunities are bound 
to such anachronistic legislation. We may also question 
if something similar accounts for Union internationale 
pour la Protection des Obtentions Végétales (UPOV, the 
first international agreement on plant variety protection, 
1961), given that differences in the membership of more 
and less developed countries are today more varied than 
in the year that treaty was drafted. This is the conclusion 
of Orlando de Ponti, former President of the International 
Seed Federation. The industrial sector has the capacity to 
provide much of the innovation needed to provide suf-
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ficient food for a growing world population, but to do so 
it needs better access to a broad variety of biotechnol-
ogy. Specific exemptions in patent laws must be clearly 
defined in order to not jeopardize future inventions. This 
clarity could also equalize the highly uneven competition 
between bigger and smaller companies, and result in en-
hanced innovative collaboration and cooperation.
Biodiversity and traditional knowledge
Yet unresolved are issues such as how should indigenous 
knowledge be treated, in what way should biodiversity be 
maintained, and how should biosafety dossiers be regu-
lated? It is important to assess to what extent those issues 
should be addressed by IP regimes, or to what extent IP 
regimes have created situations that evoke those issues.
Biodiversity is often seen as something vital, but there are 
insufficient empirical studies to provide clear evidence in 
support of such a stance. Success of promoting the con-
servation (or even enhancement) of biodiversity depends 
upon the outcomes of such studies. Similarly, claims of the 
importance of traditional knowledge as a cultural heritage 
of mankind might not be enough. Rather, what is required 
is a demonstration of those ways that indigenous scien-
tific practices and knowledge have been or real and mean-
ingful value and innovation. But, can such indigenous 
practices simply be up-taken into a global R&D effort? It 
will be evermore crucial to work on gaining indigenous 
communities as partners for long-term cooperation and 
not merely as entities to exploit or develop long term de-
pendencies after one-time transactions. Current practices 
do little to address past errors and to actively gain those 
communities as cooperation partners – a point well-noted 
by Bram De Jonge. (For his position on Benefit-Sharing 
see De Jonge, 2011 (19)).
Governance
Evidence is urgently needed to define whether current IP 
systems are efficient, promote innovation and do not un-
necessarily limit access or set unacceptable constraints for 
fostering innovations destined for poorer markets. Ingrid 
Schneider (20) has focused on the need for evidence on 
the possible negative effects of current IP regimes, such 
as the extreme expense in its demand of researchers’ time 
and resources, and the wide contingent of IP experts that 
must be financed by reallocating funds originally des-
tined for research, development, and product application. 
Also, the “one-size-fits-all” approach propagated with 
the TRIPS agreement, is less suitable for innovations in 
the life sciences than for research and development in the 
electronic, chemical or mechanical industry. (Although 
those areas are also not immune to criticism, see Bessen 
and Meurer, 2008, Chap. 3 (21)). We cannot just balance 
business opportunities lost in one area in favor of another; 
to be sure, a detailed assessment of the unused potential 
to secure human rights is required. Anything that counts 
as a setback from the realization of human rights must be 
approved by those who are subjects of those rights, i.e., 
the human beings involved as shareholders in such deci-
sions about and applications of science and technology 
research and development (22).
Worries about the actual negative impact of data exclusiv-
ity in biosafety dossiers are also a factor in the discus-
sion. Here not only issues like ever-greening of exclusive 
rights come in, but also the repetition of clinical trials 
using human subjects in which medicines are tested , not 
to show their safety, as has been already done, but to have 
additional data that are not protected in order to secure 
sales permissions as a generic manufacturer, and repeti-
tion of tests using animal subjects which are becoming 
harder to justify.
A clearer division of labor and confinement of tasks be-
tween the different stakeholders is necessary. Competition 
law, careful examination of patents, filing appeals to seem-
ingly unjust patents, making use of ‘flexibilities’ as formu-
lated in the TRIPS agreement, are all tools to counteract 
the negative effects of IP regimes, which must be used by 
governmental and civil society experts to counteract the 
misuse of power relations and balances. For example, in 
the European Union (EU), a better cooperation between 
EU and the European Patent Organisation (EPOrg) is de-
sirable to compensate for fragmentation due to national 
patent offices, and can be achieved by a relatively high 
degree of harmonization by patent granting via EPOrg.
Participation: Top-down vs. horizontal
Many important stakeholders feel that their interests and 
voice are not taken into sufficient consideration in the ne-
gotiation and drafting of IP laws. Justice demands a fairer 
distribution of objects of innovation, and an availability 
of biotechnological solutions for the problems that impact 
the poorest people of the world’s countries. Obviously, 
however, being able to participate at all levels of the in-
novation process, and having a say in research agendas 
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remains something completely out of reach for most of 
the world’s population.
Various civil society efforts have been made to foster a 
wider participation in innovation efforts. As G. Pakki 
Reddy, Executive Director Agri Biotech Foundation, 
Hyderabad (India), has noted, a solid example is the 
Indian Honey Bee Network and its collaborating institu-
tions. Those networks afford a more just distribution of 
resources, and also stimulate innovation through recogni-
tion of the work of small-scale innovators, granting them 
an opportunity to have wider publicity of their inventions. 
However, it remains to be seen how far the Indian ex-
ample of innovation and networking know-how can be 
transferred to other nations and societies.
Future policy items
It has become clear that patents exert broader effect, be-
yond simply the producers of patented technologies and 
the buyers of end-products. The existence of an object that 
is made artificially scarce by exclusive rights, which at the 
same time could alleviate problems of human welfare, is 
controversial. Similarly, having scientific infrastructure in 
place to provide technical solutions to many of the prob-
lems that afflict developing and underdeveloped nations, 
while not making full use of it speaks strongly to the need 
for a wider and more inclusive discourse to address the 
problems instantiated by current IP regimes.
In the main, we hold that the main questions for this 
discussion are:
What could be a socially desirable balance between a. 
the types of IP exclusivities innovative enterprises 
require, and the inclusive public goods protection 
such innovations are said to serve? How is this 
proper balance to be achieved?
What old and new ideas (such as Open Innovation b. 
and the Access to Knowledge movement) about 
exclusivities and their optimal integration with the 
public good and fair invention are interesting and 
worthwhile for debate, experimentation, and ulti-
mate development and use? What studies should be 
pursued?
In what way(s) can a property rights system become c. 
inclusive, not only attending to patent holders, but 
also to those stakeholders that are affected by the 
patent system?
How can inventions be stimulated that are specifi-d. 
cally designed to alleviate urgent problems and to 
reach global targets, such as the millennium devel-
opment goals and caps in gas emissions that affect 
climate change?
Why are some flexibilities of the TRIPS agreement e. 
regarding human welfare (8, a6) not used in national 
IP regimes, and why does the full potential of TRIPS 
seem to be underused? What steps can be taken to 
ensure better use of those flexibilities?
How can ethical principles and values of a nation or f. 
a group of nations be protected and what does this 
mean with respect to a broad interpretation of the 
ordre public and public policy exemptions to patent-
ability (8, a27.2 and a27.3)?
This discourse should be inclusive: involving all parties, 
not only patent holders, industrial countries and their 
governmental officials. Moreover, it is important to focus 
on general challenges, such as the place of IP rights in 
a pluralist world, rather than on specific situations and 
environments. We should analyse the greater picture and 
make an overall judgement.
Future research issues
Five major research issues can make the recommended 
public discourse and ultimately science and technology 
IP rights more relevant to current and future conditions in 
a global economy:
First, taking into account the lack of transparency, and 
to make the patent system more accessible to non-patent 
holders, mechanisms should be developed to make public, 
comprehensible and not misleading all information about 
patent files. This information should be made publicly 
available without restricted access.
Second, research is necessary to answer the question how, 
given the democratization of information, the current IP 
system can be made more democratic, (e.g., by including 
the voices of non-patent holders).
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Third, research is required into alternatives, complements 
and other, new ideas to achieve a balanced relation be-
tween exclusive entitlements and inclusive ends-in-view 
that comprise public goods (such as open innovation, Ac-
cess to Knowledge (A2K), common pools, alternatives 
and complements to the current IP regimes). Equity and 
inclusivity should be leading principles, both in intention 
and outcome (impact).
Fourth, further inquiry is required to examine other, free-
dom restricting regulations or practices, such as steward 
regulations concerning biosafety dossiers of patented 
inventions, which allow owners to keep those dossiers 
restricted from public access without time limits.
Fifth, research is needed to assess the social and techno-
logical impacts of current IP systems and of alternatives, 
taking into account inter alia questions of stakeholder in-
volvement and how it might prevent power relationships 
determine unfair use of property systems.
Concluding ethical reflection
Intellectual property rights are a means to an end – and the 
current regime is only one of many conceivable systems of 
incentives. The current regime can be praised for bringing 
out many inventions that have benefited a wide public, 
but the IP system also faces a serious charge of sustaining 
a specific culture of developing products and doing scien-
tific work that may be directly at odds with the needs and 
vulnerabilities of a significant number of people. If this 
charge is indeed related to the current IP regime, we have 
to ask ourselves what responsibilities and duties arise to 
mitigate and remedy this effect. Part of this charge claims 
that the current IP regime is privatizing the very building 
blocks of further research and development – components 
that were once part of the commons. The public domain, 
in contrast to the private domain, may in fact be a locus of 
much more diverse forms of creativity that also ensure a 
plurality of ideas, traditions, and translations.
Antony Taubman stated during the conference that “IP 
law or treaty may be greater than the sum of its parts”. 
We can see this in ordre public clauses in patent law that 
are conceptualized to avoid the creation of incentives that 
create objects that are socially undesirable, and/or are 
perceived to be offensive by the general public. During 
this last decade, the world is coping with disastrous ef-
fects of financial hubris on public welfare, and economic 
rationality is evermore widely seen as secondary to social 
and political welfare. Moreover, the old concept of ordre 
public may need to be revised and expanded, parallel to 
the way public morality has expanded from a set of values 
and duties that only were valid for a smaller community, 
to the now more predominant cosmopolitan sense of jus-
tice. The IP regime must do justice to this sense of public 
morality because is dependent upon civil support. Here 
we inevitably confront the question of who shall be the 
moral gatekeeper in deciding what are “good” exclusive 
rights and what are “bad” exclusive rights. It may be that 
the democratization of the current IP regimes is a first step 
to respond to this problem.
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